good_老虎社区_美港股上老虎

G7
2021-11-22

good

Fujifilm to spend $5bn to become global contract drugmaker

Opportunity seen in outsourcing trend similar to chip industry Fujifilm plans to introduce a new pro

Fujifilm to spend $5bn to become global contract drugmaker

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":872551136,"tweetId":"872551136","gmtCreate":1637550625535,"gmtModify":1637550650552,"author":{"id":3575098910724577,"idStr":"3575098910724577","authorId":3575098910724577,"authorIdStr":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>good</p></body></html>","htmlText":"<html><head></head><body><p>good</p></body></html>","text":"good","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872551136","repostId":1108872503,"repostType":4,"repost":{"id":"1108872503","kind":"news","pubTimestamp":1637550331,"share":"https://www.laohu8.com/m/news/1108872503?lang=&edition=full","pubTime":"2021-11-22 11:05","market":"us","language":"en","title":"Fujifilm to spend $5bn to become global contract drugmaker","url":"https://stock-news.laohu8.com/highlight/detail?id=1108872503","media":"Nikkei Asia","summary":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new pro","content":"<p>Opportunity seen in outsourcing trend similar to chip industry</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cffcbada03c1878d7dd688d377607e1\" tg-width=\"1400\" tg-height=\"787\" width=\"100%\" height=\"auto\"><span>Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)</span></p>\n<p>TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.</p>\n<p>The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.</p>\n<p>As in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.</p>\n<p>As new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.</p>\n<p>Another factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.</p>\n<p>Developing a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.</p>\n<p>Takahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e0ef42e741341d1e8a618f8564c23\" tg-width=\"770\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Fujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)</span></p>\n<p>In fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.</p>\n<p>Research and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.</p>\n<p>In particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth</p>\n<p>Fujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"</p>\n<p>Fujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.</p>\n<p>Continuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.</p>\n<p>Takatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.</p>\n<p>Fujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujifilm to spend $5bn to become global contract drugmaker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujifilm to spend $5bn to become global contract drugmaker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 11:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker><strong>Nikkei Asia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K...</p>\n\n<a href=\"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUJIF":"FUJIFILM Holdings Corp."},"source_url":"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108872503","content_text":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)\nTOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.\nThe Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.\nAs in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.\nAs new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.\nAnother factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.\nDeveloping a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.\nTakahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.\nFujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)\nIn fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.\nResearch and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.\nIn particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth\nFujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"\nFujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.\nContinuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.\nTakatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.\nFujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":557,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Fujifilm to spend $5bn to become global contract drugmaker

评论（2）

热议股票